WO2007078157A1 - Fomitopsis pinicola extract and a process for manufacturing the same - Google Patents
Fomitopsis pinicola extract and a process for manufacturing the same Download PDFInfo
- Publication number
- WO2007078157A1 WO2007078157A1 PCT/KR2007/000055 KR2007000055W WO2007078157A1 WO 2007078157 A1 WO2007078157 A1 WO 2007078157A1 KR 2007000055 W KR2007000055 W KR 2007000055W WO 2007078157 A1 WO2007078157 A1 WO 2007078157A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- extract
- fomitopsis pinicola
- composition according
- diabetes mellitus
- pieces
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 105
- 241000123150 Fomitopsis pinicola Species 0.000 title claims abstract description 91
- 238000000034 method Methods 0.000 title description 9
- 238000004519 manufacturing process Methods 0.000 title description 2
- 230000008569 process Effects 0.000 title description 2
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 54
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 44
- 230000000694 effects Effects 0.000 claims abstract description 44
- 102000016912 Aldehyde Reductase Human genes 0.000 claims abstract description 37
- 108010053754 Aldehyde reductase Proteins 0.000 claims abstract description 37
- 208000002249 Diabetes Complications Diseases 0.000 claims abstract description 25
- 208000031226 Hyperlipidaemia Diseases 0.000 claims abstract description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 40
- 239000003513 alkali Substances 0.000 claims description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 16
- 201000010099 disease Diseases 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 208000002177 Cataract Diseases 0.000 claims description 8
- 208000001647 Renal Insufficiency Diseases 0.000 claims description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 8
- 239000012153 distilled water Substances 0.000 claims description 8
- 201000006370 kidney failure Diseases 0.000 claims description 8
- 239000002244 precipitate Substances 0.000 claims description 8
- 244000061456 Solanum tuberosum Species 0.000 claims description 7
- 235000002595 Solanum tuberosum Nutrition 0.000 claims description 7
- 239000000706 filtrate Substances 0.000 claims description 7
- 238000012258 culturing Methods 0.000 claims description 5
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 238000005520 cutting process Methods 0.000 claims description 4
- 230000003472 neutralizing effect Effects 0.000 claims description 4
- 230000001376 precipitating effect Effects 0.000 claims description 4
- 238000010298 pulverizing process Methods 0.000 claims description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 4
- 239000000243 solution Substances 0.000 claims description 4
- 230000008961 swelling Effects 0.000 claims description 4
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 2
- 238000004108 freeze drying Methods 0.000 claims description 2
- 230000001629 suppression Effects 0.000 claims description 2
- 238000005406 washing Methods 0.000 claims description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 30
- 238000008214 LDL Cholesterol Methods 0.000 abstract description 13
- 235000012000 cholesterol Nutrition 0.000 abstract description 10
- 150000003626 triacylglycerols Chemical class 0.000 abstract description 8
- 230000036765 blood level Effects 0.000 abstract description 6
- 230000002207 retinal effect Effects 0.000 abstract description 5
- 235000013376 functional food Nutrition 0.000 abstract description 4
- 238000011161 development Methods 0.000 abstract description 3
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 28
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 28
- 229960001052 streptozocin Drugs 0.000 description 28
- 239000008280 blood Substances 0.000 description 22
- 210000004369 blood Anatomy 0.000 description 22
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 11
- 241000700159 Rattus Species 0.000 description 11
- 239000008103 glucose Substances 0.000 description 11
- 235000005911 diet Nutrition 0.000 description 8
- 210000003734 kidney Anatomy 0.000 description 8
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 239000000600 sorbitol Substances 0.000 description 6
- 235000000346 sugar Nutrition 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108010010234 HDL Lipoproteins Proteins 0.000 description 5
- 208000035150 Hypercholesterolemia Diseases 0.000 description 5
- 230000037213 diet Effects 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- 229920005862 polyol Polymers 0.000 description 5
- 150000003077 polyols Chemical class 0.000 description 5
- 229920001282 polysaccharide Polymers 0.000 description 5
- 239000005017 polysaccharide Substances 0.000 description 5
- 230000003449 preventive effect Effects 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 5
- 235000019786 weight gain Nutrition 0.000 description 5
- 230000004584 weight gain Effects 0.000 description 5
- 150000004676 glycans Chemical class 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 3
- 208000011514 Familial renal glucosuria Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 230000000378 dietary effect Effects 0.000 description 3
- 235000012631 food intake Nutrition 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000011987 methylation Effects 0.000 description 3
- 238000007069 methylation reaction Methods 0.000 description 3
- 230000008723 osmotic stress Effects 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 208000007278 renal glycosuria Diseases 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 2
- 108010005094 Advanced Glycation End Products Proteins 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- 102000005548 Hexokinase Human genes 0.000 description 2
- 108700040460 Hexokinases Proteins 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- ACFIXJIJDZMPPO-NNYOXOHSSA-N NADPH Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](OP(O)(O)=O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 ACFIXJIJDZMPPO-NNYOXOHSSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 230000006538 anaerobic glycolysis Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 238000004817 gas chromatography Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 239000003456 ion exchange resin Substances 0.000 description 2
- 229920003303 ion-exchange polymer Polymers 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- DSAKBVMOWYDGMT-JNSGDMPLSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxy-2,3,4-trimethylheptanal Chemical compound CC(O)[C@@H](O)[C@@](C)(O)[C@](C)(O)[C@@](C)(O)C=O DSAKBVMOWYDGMT-JNSGDMPLSA-N 0.000 description 1
- WHFPFDLCPDSWML-FLNDETTGSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxy-2,4-dimethylheptanal Chemical compound CC(O)[C@@H](O)[C@@](C)(O)[C@H](O)[C@@](C)(O)C=O WHFPFDLCPDSWML-FLNDETTGSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 1
- 229920002498 Beta-glucan Polymers 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- 239000011665 D-biotin Substances 0.000 description 1
- 235000000638 D-biotin Nutrition 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 240000008397 Ganoderma lucidum Species 0.000 description 1
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 108010009384 L-Iditol 2-Dehydrogenase Proteins 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010033627 Pancreatic injury Diseases 0.000 description 1
- 102100026974 Sorbitol dehydrogenase Human genes 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- FMRLDPWIRHBCCC-UHFFFAOYSA-L Zinc carbonate Chemical compound [Zn+2].[O-]C([O-])=O FMRLDPWIRHBCCC-UHFFFAOYSA-L 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- RJGDLRCDCYRQOQ-UHFFFAOYSA-N anthrone Chemical compound C1=CC=C2C(=O)C3=CC=CC=C3CC2=C1 RJGDLRCDCYRQOQ-UHFFFAOYSA-N 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
- 239000001527 calcium lactate Substances 0.000 description 1
- 235000011086 calcium lactate Nutrition 0.000 description 1
- 229960002401 calcium lactate Drugs 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- OIDPCXKPHYRNKH-UHFFFAOYSA-J chrome alum Chemical compound [K]OS(=O)(=O)O[Cr]1OS(=O)(=O)O1 OIDPCXKPHYRNKH-UHFFFAOYSA-J 0.000 description 1
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229940116318 copper carbonate Drugs 0.000 description 1
- GEZOTWYUIKXWOA-UHFFFAOYSA-L copper;carbonate Chemical compound [Cu+2].[O-]C([O-])=O GEZOTWYUIKXWOA-UHFFFAOYSA-L 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000007882 dietary composition Nutrition 0.000 description 1
- 235000018823 dietary intake Nutrition 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000009207 exercise therapy Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229960002413 ferric citrate Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol Substances OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000002434 immunopotentiative effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 230000037041 intracellular level Effects 0.000 description 1
- NPFOYSMITVOQOS-UHFFFAOYSA-K iron(III) citrate Chemical compound [Fe+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NPFOYSMITVOQOS-UHFFFAOYSA-K 0.000 description 1
- 238000002350 laparotomy Methods 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- INHCSSUBVCNVSK-UHFFFAOYSA-L lithium sulfate Inorganic materials [Li+].[Li+].[O-]S([O-])(=O)=O INHCSSUBVCNVSK-UHFFFAOYSA-L 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- XMWCXZJXESXBBY-UHFFFAOYSA-L manganese(ii) carbonate Chemical compound [Mn+2].[O-]C([O-])=O XMWCXZJXESXBBY-UHFFFAOYSA-L 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 description 1
- 229910052939 potassium sulfate Inorganic materials 0.000 description 1
- 235000011151 potassium sulphates Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- 238000012205 qualitative assay Methods 0.000 description 1
- 230000000979 retarding effect Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000011781 sodium selenite Substances 0.000 description 1
- 235000015921 sodium selenite Nutrition 0.000 description 1
- 229960001471 sodium selenite Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- RBTVSNLYYIMMKS-UHFFFAOYSA-N tert-butyl 3-aminoazetidine-1-carboxylate;hydrochloride Chemical compound Cl.CC(C)(C)OC(=O)N1CC(N)C1 RBTVSNLYYIMMKS-UHFFFAOYSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940045999 vitamin b 12 Drugs 0.000 description 1
- 229940021056 vitamin d3 Drugs 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- 239000011667 zinc carbonate Substances 0.000 description 1
- 235000004416 zinc carbonate Nutrition 0.000 description 1
- 229910000010 zinc carbonate Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
Definitions
- the present invention relates to a Fomitopsis pinicola extract and the use thereof.
- the present invention relates to the fruit body extracts and cultured mycelial extract of Fomitopsis pinicola, which are effectively preventive or suppressive of diseases attributable to the increased activity of aldose reductase, including diabetes complications, such as cataracts, renal failure, etc., and diabetes mellitus-induced hyperlipidemia.
- diabetes complications such as cataracts, renal failure, etc.
- diabetes mellitus-induced hyperlipidemia including diabetes complications, such as cataracts, renal failure, etc.
- Diabetes mellitus is generally classified into type 1 and type 2, which are dependent on and independent of insulin, respectively. Approximately 90 to 95% of diabetes mellitus is observed to be type 2. Aside from acute glucose level abnormalities, the main risks to health, when diabetes mellitus occurs due to hormonal unbalance, are the characteristic long-term complications. These include arteriosclerosis, cardiovascular diseases, nerve damage, and renal failure, leading to death. This is believed to be attributed to a serious change which is brought about in lipid metabolism to increase levels of triglyceride, total cholesterol, and LDL cholesterol and decrease the level of HDL in the blood.
- AGEs advanced glycation end products
- Fomitopsis pinicola a Korean autogenous mushroom, was thought to be extinct, but has recently been discovered again. It was renamed ' Jeseng' and registered in the National Seed Management Office, Korea (Application No.: 2003-498). Fomitopsis pinicola grows with attachment to a wood stem and is leathery to woody, and hoof- shaped or shelved. The upper surface is usually zoned, and has a wide range in color from dark brown through grey to black, with a red band near the margin. Many mushrooms have been extensively reported to contain not only various nutrients but also various types of physiological substances useful in the prevention and treatment of metabolic diseases, such as diabetes mellitus, hyperlipidemia and arteriosclerosis, and effective for anticancer activity and immunopotentiation.
- metabolic diseases such as diabetes mellitus, hyperlipidemia and arteriosclerosis, and effective for anticancer activity and immunopotentiation.
- Fomitopsis pinicola is known to have inhibitory activity against tumors, and has recently been reported to reduce blood sugar levels (refer to Korean Pat. Laid-Open Publication No. 2005-60726).
- Fomitopsis pinicola has not been sufficiently studied for physiological activity.
- physiologically active principles of Fomitopsis pinicola remain unidentified. Therefore, it is required to assay Fomitopsis pinicola for various physiological activities, develop a method for preparing extracts from the fruit body and cultured mycelia of Fomitopsis pinicola, and analyze constituents of the extracts. Disclosure of Invention Technical Problem
- Fomitopsis pinicola capable of preventing or suppressing diabetes complications or diabetes-induced hyperlipidemia, conducted by the present inventors, resulted in the finding that extracts from the fruit body and cultured mycelia of Fomitopsis pinicola inhibits the activity of aldose reductase in the eye lens and the kidneys and reduces the level of triglycerides, total cholesterol and LDL cholesterol in the blood.
- the principle which brings about these inhibitory effects was analyzed to be ' ⁇ -l,3-glucano- ⁇ -l,6-heterogalactomannan-protein complex' .
- compositions effective for the prevention or suppression of diseases attributable to the increased activity of aldose reductase or diabetes mellitus-induced hyperlipidemia, comprising a fruit body extract or cultured mycelial extract of Fomitopsis pinicola.
- the fruit body extract is a hot- water extract or an alkali extract.
- the hot- water extract may be prepared by cutting Fomitopsis pinicola fruit bodies into fine pieces, pulverizing the pieces, heating the pulverized pieces in water, concentrating the aqueous solution, precipitating the solution with ethanol, and freeze- drying the precipitate, in order.
- the pulverized pieces of the fruit bodies are heated at 100°C for 24 hours and the aqueous solution is concentrated at 40°C to one tenth of the initial volume.
- the alkali extract may be prepared by cutting Fomitopsis pinicola fruit bodies into fine pieces, pulverizing the pieces, swelling the pulverized pieces in IN KOH, homogenizing the pieces, filtrating the homogenate, neutralizing the filtrate, washing the neutralized filtrate with distilled water, and drying the washed filtrate at 60°C, in order.
- the pulverized pieces of the fruit bodies are mixed with IN KOH in a ratio of 1:1 (w/v), left to swell for 1 hour, homogenized, filtered through a 100 mesh sieve, and neutralized with cone. HCl.
- the cultured mycelial extract may be prepared by seed- and sub-culturing mycelia of Fomitopsis pinicola, inoculating the mycelia in a sterile and cold potato medium, neutralizing the culture, precipitating with ethanol, and dialyzing the precipitate against distilled water.
- the mycelia are inoculated in the potato medium to an amount of 2% (v/v), and the culture is neutralized with sodium hydrogen carbonate (NaHCO ) to a pH of 6.5.
- NaHCO sodium hydrogen carbonate
- the diseases attributable to the increased activity of aldose reductase include a diabetes mellitus complication.
- the diabetes mellitus complication is cataract or renal failure.
- FIG. 1 is a diagram showing the mechanism of the incidence of diabetes mellitus and complications thereof. Because aldose reductase is responsible for the reduction of glucose to sorbitol in the polyol pathway, the inhibition of the activity thereof prevents the incidence of diabetes mellitus complications.
- FIG. 2 is a graph in which the activity of retinal aldose reductase is plotted against the dose of the Fomitopsis pinicola fruit body hot- water extract.
- FIG. 3 is a graph showing kinetics of the retinal aldose reductase according to the dose of Fomitopsis pinicola fruit body hot- water extract. Best Mode for Carrying Out the Invention
- the present invention is directed to an extract from the fruit body or cultured mycelia of Fomitopsis pinicola, and a composition comprising the extract as an active ingredient for preventing or suppressing the diseases attributable to the increased activity of aldose reductase, including diabetes complications, such as cataracts and renal failure, and diabetes-induced hypercholesterolemia.
- the extract from the fruit body of Fomitopsis pinicola may be prepared with hot water or alkali.
- a hot- water extract from the fruit body of Fomitopsis pinicola can be obtained as follows.
- the fruit body is finely cut, pulverized, immersed in water, and heated, followed by concentration and precipitation with ethanol.
- the precipitate is then freeze-dried.
- Water is preferably used in an amount of about 30 times the weight of the pulverized fruit body, but is not limited to that amount.
- Heating is preferably conducted at 100°C for about 24 hrs, but is not limited thereto.
- the con- centration it is preferable that the supernatant be evaporated at 40°C until the final volume is reduced to one tenth of the initial volume.
- An alkaline extract from the fruit body of Fomitopsis pinicola can be obtained as follows.
- the fruit body is finely cut, pulverized and left to swell for 1 hr in IN KOH, followed by homogenization using a homogenizer.
- the homogenate is filtered through a 100 mesh sieve, neutralized with cone. HCl, washed with distilled water, and then dried at 60°C.
- IN KOH it is preferable that IN KOH be used at a ratio of approximately 1:1 (w/v).
- HAS homoogenization after alkali swelling
- diabetes complications such as cataracts or renal failure
- diabetes complications such as cataracts or renal failure
- sorbitol reduced from glucose by aldose reductase
- osmotic stress due to its low permeability through the cell membrane, thus injuring the eye lens, the retina, and the glomeruli of the kidneys (refer to FIG. 1).
- the extract from Fomitopsis pinicola according to the present invention was assayed for preventive or suppressive activity against diseases attributable to the increased activity of aldose reductase and diabetes-induced hyperlipidemia as follows. First, the extract was orally administered to rats in which diabetes mellitus had been induced with STZ (streptozotocin). After being raised, each rat was sacrificed to excise the eye lens and kidneys, which were then homogenized in ice. The homogenate was analyzed for the activity of aldose reductase, having an influence on the incidence of diabetes complications. In addition, blood samples were measured for levels of triglycerides, total cholesterol, HDL cholesterol, and LDL cholesterol to determine whether the extract of the present invention could inhibit diabetes-induced hyperlipidemia.
- STZ streptozotocin
- the Fomitopsis pinicola extract is analyzed for ingredients and the molecular weights thereof.
- the Fomitopsis pinicola extract was fractioned and purified through DEAE-cellulose ion exchange resin and a Sepharose CL-4B gel column, followed by methylation analysis using gas chromatography.
- the mycelia were inoculated in a sterilized (120°C, 30 min), cold potato medium (water: 16 L, potato powder: 300 g, glucose: 150 g, peptone: 0.1 g) to an amount of 2% (v/v), and cultured at 30°C for 10 days in a rotary agitator operating at 150 rpm with sterile air (10cm /min) provided thereto. Then, neutralization with sodium hydrogen carbonate (NaHCO ) to a pH of 6.5 was conducted, followed by precipitation with 10 volumes of ethanol.
- NaHCO sodium hydrogen carbonate
- EXAMPLE 2-1 Experimental Animals and Method [53] SD male rats, each having body weight of 200+5 g, were divided into 5 groups of 7, which were respectively set as a normal control group (NC), a diabetes mellitus control group (DM), in which diabetes mellitus was induced through STZ, a diabetes mellitus- induced, hot-water extract-administered group (DM-WE) which was administered with 1% of the hot- water extract after treatment with STZ, a diabetes mellitus-induced, alkali extract-administered group (DM-AE) which was administered with 1% of the alkali extract after treatment with STZ, and a diabetes mellitus-induced, cultured mycelial extract- administered group (DM-CM) which was administered with 1 % of the cultured mycelial extract after treatment with STZ.
- NC normal control group
- DM-WE diabetes mellitus- induced, hot-water extract-administered group
- DM-AE diabetes mellit
- Each of the groups was reared for four weeks according to the dietary schedules of Table 1, below.
- STZ streptozotocin 55 mg/kg
- NC normal control
- DM diabetes mellitus control
- DM-WE 1% of Fomitopsis pinicola fruit body hot-water extract was administered after treatment with STZ
- DM- AE 1% of Fomitopsis pinicola fruit body alkali extract was administered after treatment with STZ
- DM-CM 1% of the cultured mycelial extract of Fomitopsis pinicola was administered after treatment with STZ
- Diabetes complications such as cataracts, peripheral neuritis, pancreatic injury, etc.
- the polyol pathway takes place when hexokinase, which serves as the first step enzyme in anaerobic glycolysis, is saturated.
- Excess glucose is reduced to sorbitol via aldose reductase, the first step enzyme in the polyol pathway.
- An abundance of intracellular sorbitol generates osmotic stress due to its low permeability through the cell membrane, so that an excessive amount of water is introduced into the cell, thus injuring the non-insulin dependent organs, such as eye lenses, peripheral nerves, and the kidneys.
- aldose reductase was analyzed according to the method of Hayman and Kinoshita (1965), in which, while lithium sulfate, NADPH and DL- ⁇ -glycerol were reacted at 25°C in the presence of the enzyme in 50 mM PBS (pH 6.2), decreasing NADPH levels were measured at 340 nm.
- EXAMPLE 2-2-1 Suppressive effect on activity of aldose reductase in eye lens
- [83] The same experimental groups and diets as in Example 2 were conducted. Following the diet programs for 4 weeks, the five experimental groups were measured for blood levels of triglycerides, total cholesterol, LDL cholesterol and HDL cholesterol. For the measurement of blood levels of triglycerides, total cholesterol and HDL cholesterol, commercially available kits were used (AM 157S-K, AM 202-K, AM 203-K, Asanpharm Co., Korea). The level of LDL cholesterol in the blood was calculated according to the method of Fridwell et al. (1972).
- NC normal control
- DM diabetes mellitus control
- DM-WE 1% of Fomitopsis pinicola fruit body hot-water extract was administered after treatment with STZ
- DM- AE 1% of Fomitopsis pinicola fruit body alkali extract was administered after treatment with STZ
- DM-CM 1% of the cultured mycelial extract of Fomitopsis pinicola was administered after treatment with STZ
- NC normal control
- DM diabetes mellitus control
- DM-WE 1% of Fomitopsis pinicola fruit body hot-water extract was administered after treatment with STZ
- DM- AE 1% of Fomitopsis pinicola fruit body alkali extract was administered after treatment with STZ
- DM-CM 1% of the cultured mycelial extract of Fomitopsis pinicola was administered after treatment with STZ
- NC normal control
- DM diabetes mellitus control
- DM-WE 1% of Fomitopsis pinicola fruit body hot-water extract was administered after treatment with STZ
- DM- AE 1% of Fomitopsis pinicola fruit body alkali extract was administered after treatment with STZ
- DM-CM 1% of the cultured mycelial extract of Fomitopsis pinicola was administered after treatment with STZ
- Fomitopsis pinicola extracts of the present invention were identified as preventors of diabetes mellitus complications as well as suppressors of diabetes mellitus-induced hyperlipidemia, as evident in Examples 2 and 3. In order to examine the principle of the effects, the Fomitopsis pinicola extracts were qualitatively analyzed.
- Fomitopsis pinicola fruit hot- water extract the Fomitopsis pinicola fruit body alkali extract, and the cultured mycelial extract of Fomitopsis pinicola, prepared as described above, were fractioned and purified through DEAE-Cellulose (Cl ) ion exchange resin and Sepharose CL-4B gel according to a well-known method (see, Lee Shin young, Kang Tae soo, Structure Analysis of Antitumoral Exo-polysaccharide (BWS) obtained from submerged cultivation of Ganoderma lucidum mycelium, The Korean J. Mycology, 27: 76-81, (1999)), followed by methylation analysis using gas chromatography.
- DEAE-Cellulose (Cl ) ion exchange resin and Sepharose CL-4B gel according to a well-known method (see, Lee Shin young, Kang Tae soo, Structure Analysis of Antitumoral Exo-polysaccharide (BWS) obtained from submerged cultivation of Ganoderma lucid
- dextran having MWs of 2,000,000, 500,000, and 300,000 (Sigma) was used. Absorbance at 280 nm was utilized to detect the protein composition of the fractions. Six-carbon sugars were analyzed according to the anthrone method (see, Spiro RG, Analysis of sugars found in glycoprotein in Method in Enzymology, Academic Press, New York 8: 4-10, (1966)).
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Disclosed herein are Fomitopsis pinicola extracts and use thereof. Fruit body extracts and cultured mycelial extracts of Fomitopsis pinicola effectively inhibit the renal and retinal aldose reductase activity and decrease blood levels of triglycerides, total cholesterol and LDL cholesterol, thereby finding various applications for the development of functional foods for preventing diabetes mellitus complications and suppressing diabetes mellitus-induced hyperlipidemia.
Description
FOMITOPSIS PINICOLA EXTRACT AND A PROCESS FOR MANUFACTURING THE SAME
Technical Field
[1] The present invention relates to a Fomitopsis pinicola extract and the use thereof.
More particularly, the present invention relates to the fruit body extracts and cultured mycelial extract of Fomitopsis pinicola, which are effectively preventive or suppressive of diseases attributable to the increased activity of aldose reductase, including diabetes complications, such as cataracts, renal failure, etc., and diabetes mellitus-induced hyperlipidemia. Background Art
[2] With the westernization of the diet, lifestyle-related diseases, such as obesity, hyperlipidemia, diabetes, etc., are occurring at an incidence rate that is increasing in recent years, which is now emerging as a serious social problem in Asia, including Korea. In particular, the incidence rate of diabetes in Korea has drastically increased in the last decade, ranking as the 4th cause of death of Koreans (see Annual Report on Fatality Statistics in 1999, 2002).
[3] Diabetes mellitus is generally classified into type 1 and type 2, which are dependent on and independent of insulin, respectively. Approximately 90 to 95% of diabetes mellitus is observed to be type 2. Aside from acute glucose level abnormalities, the main risks to health, when diabetes mellitus occurs due to hormonal unbalance, are the characteristic long-term complications. These include arteriosclerosis, cardiovascular diseases, nerve damage, and renal failure, leading to death. This is believed to be attributed to a serious change which is brought about in lipid metabolism to increase levels of triglyceride, total cholesterol, and LDL cholesterol and decrease the level of HDL in the blood.
[4] Upon the onset of hyperglycemia, which is one of the classic symptoms of diabetes mellitus, glucose enters either glycolysis or the polyol pathway. The latter case occurs when hexokinase, which is involved in anaerobic glycolysis, is saturated so that excess glucose is reduced to sorbitol via aldose reductase and then metabolized to fructose via sorbitol dehydrogenase. An abundance of intracellular sorbitol generates osmotic stress due to its low permeability through the cell membrane, thus injuring tissue cells. In addition, excessive glucose and excessively generated fructose may be associated with
proteins to form advanced glycation end products (AGEs), which are thought to be major factors in aging and age related chronic diseases. They are also believed to play a causative role in the vascular complications of diabetes mellitus.
[5] To treat diabetes mellitus, dietary or exercise therapy is usually conducted along with drug therapy. All of these therapies function to maintain a normal blood glucose level with the aim of preventing or retarding diabetes complications. Although extensive studies and research have been conducted on diabetes complications and diabetes-induced hypercholesterolemia, no perfect cures have been established. Thus, intensive and keen attention is paid to functional foods or medications for preventing or suppressing the onset of diabetes complication or diabetes-induced hypercholesterolemia.
[6] Fomitopsis pinicola, a Korean autogenous mushroom, was thought to be extinct, but has recently been discovered again. It was renamed ' Jeseng' and registered in the National Seed Management Office, Korea (Application No.: 2003-498). Fomitopsis pinicola grows with attachment to a wood stem and is leathery to woody, and hoof- shaped or shelved. The upper surface is usually zoned, and has a wide range in color from dark brown through grey to black, with a red band near the margin. Many mushrooms have been extensively reported to contain not only various nutrients but also various types of physiological substances useful in the prevention and treatment of metabolic diseases, such as diabetes mellitus, hyperlipidemia and arteriosclerosis, and effective for anticancer activity and immunopotentiation.
[7] Fomitopsis pinicola is known to have inhibitory activity against tumors, and has recently been reported to reduce blood sugar levels (refer to Korean Pat. Laid-Open Publication No. 2005-60726). However, Fomitopsis pinicola has not been sufficiently studied for physiological activity. Further, physiologically active principles of Fomitopsis pinicola remain unidentified. Therefore, it is required to assay Fomitopsis pinicola for various physiological activities, develop a method for preparing extracts from the fruit body and cultured mycelia of Fomitopsis pinicola, and analyze constituents of the extracts. Disclosure of Invention Technical Problem
[8] Leading to the present invention, intensive and thorough research into a material of
Fomitopsis pinicola capable of preventing or suppressing diabetes complications or diabetes-induced hyperlipidemia, conducted by the present inventors, resulted in the finding that extracts from the fruit body and cultured mycelia of Fomitopsis pinicola inhibits the activity of aldose reductase in the eye lens and the kidneys and reduces the level of triglycerides, total cholesterol and LDL cholesterol in the blood. In addition,
the principle which brings about these inhibitory effects was analyzed to be 'β-l,3-glucano-β-l,6-heterogalactomannan-protein complex' .
[9] It is therefore an object of the present invention to provide a fruit body extract or cultured mycelial extract of Fomitopsis pinicola which can prevent or suppress the diseases attributable to the increased activity of aldose reductase, including diabetes complications, such as cataracts and renal failure, and diabetes-induced hypercholesterolemia.
[10] It is another object of the present invention to provide a composition based on the fruit body extract or cultured mycelial extract of Fomitopsis pinicola, which is useful in the treatment and prevention of diseases attributable to the increased activity of aldose reductase, including diabetes complications, such as cataracts and renal failure, and diabetes-induced hypercholesterolemia. Technical Solution
[11] In order to accomplish the above objects, there is provided a composition, effective for the prevention or suppression of diseases attributable to the increased activity of aldose reductase or diabetes mellitus-induced hyperlipidemia, comprising a fruit body extract or cultured mycelial extract of Fomitopsis pinicola.
[12] In a preferred embodiment, the fruit body extract is a hot- water extract or an alkali extract.
[13] The hot- water extract may be prepared by cutting Fomitopsis pinicola fruit bodies into fine pieces, pulverizing the pieces, heating the pulverized pieces in water, concentrating the aqueous solution, precipitating the solution with ethanol, and freeze- drying the precipitate, in order.
[14] Preferably, the pulverized pieces of the fruit bodies are heated at 100°C for 24 hours and the aqueous solution is concentrated at 40°C to one tenth of the initial volume.
[15] The alkali extract may be prepared by cutting Fomitopsis pinicola fruit bodies into fine pieces, pulverizing the pieces, swelling the pulverized pieces in IN KOH, homogenizing the pieces, filtrating the homogenate, neutralizing the filtrate, washing the neutralized filtrate with distilled water, and drying the washed filtrate at 60°C, in order.
[16] Preferably, the pulverized pieces of the fruit bodies are mixed with IN KOH in a ratio of 1:1 (w/v), left to swell for 1 hour, homogenized, filtered through a 100 mesh sieve, and neutralized with cone. HCl.
[17] The cultured mycelial extract may be prepared by seed- and sub-culturing mycelia of Fomitopsis pinicola, inoculating the mycelia in a sterile and cold potato medium, neutralizing the culture, precipitating with ethanol, and dialyzing the precipitate against distilled water.
[18] Preferably, the mycelia are inoculated in the potato medium to an amount of 2%
(v/v), and the culture is neutralized with sodium hydrogen carbonate (NaHCO ) to a pH of 6.5.
[19] The diseases attributable to the increased activity of aldose reductase include a diabetes mellitus complication.
[20] In a preferred embodiment, the diabetes mellitus complication is cataract or renal failure. Advantageous Effects
[21] Fruit body extracts and cultured mycelial extracts of Fomitopsis pinicola according to the present invention effectively inhibit the renal and retinal aldose reductase activity and decrease blood levels of triglycerides, total cholesterol and LDL cholesterol, thereby finding various applications for the development of functional foods for preventing diabetes mellitus complications and suppressing diabetes mellitus-induced hyperlipidemia. Brief Description of the Drawings
[22] FIG. 1 is a diagram showing the mechanism of the incidence of diabetes mellitus and complications thereof. Because aldose reductase is responsible for the reduction of glucose to sorbitol in the polyol pathway, the inhibition of the activity thereof prevents the incidence of diabetes mellitus complications.
[23] FIG. 2 is a graph in which the activity of retinal aldose reductase is plotted against the dose of the Fomitopsis pinicola fruit body hot- water extract.
[24] FIG. 3 is a graph showing kinetics of the retinal aldose reductase according to the dose of Fomitopsis pinicola fruit body hot- water extract. Best Mode for Carrying Out the Invention
[25] In accordance with an aspect thereof, the present invention is directed to an extract from the fruit body or cultured mycelia of Fomitopsis pinicola, and a composition comprising the extract as an active ingredient for preventing or suppressing the diseases attributable to the increased activity of aldose reductase, including diabetes complications, such as cataracts and renal failure, and diabetes-induced hypercholesterolemia.
[26] In the present invention, the extract from the fruit body of Fomitopsis pinicola may be prepared with hot water or alkali.
[27] A hot- water extract from the fruit body of Fomitopsis pinicola can be obtained as follows. The fruit body is finely cut, pulverized, immersed in water, and heated, followed by concentration and precipitation with ethanol. The precipitate is then freeze-dried. Water is preferably used in an amount of about 30 times the weight of the pulverized fruit body, but is not limited to that amount. Heating is preferably conducted at 100°C for about 24 hrs, but is not limited thereto. As for the con-
centration, it is preferable that the supernatant be evaporated at 40°C until the final volume is reduced to one tenth of the initial volume.
[28] An alkaline extract from the fruit body of Fomitopsis pinicola can be obtained as follows. The fruit body is finely cut, pulverized and left to swell for 1 hr in IN KOH, followed by homogenization using a homogenizer. The homogenate is filtered through a 100 mesh sieve, neutralized with cone. HCl, washed with distilled water, and then dried at 60°C. For the swelling, it is preferable that IN KOH be used at a ratio of approximately 1:1 (w/v). This alkaline extraction, called HAS (homogenization after alkali swelling) method, is exceptionally improved in yield over conventional methods.
[29] Extraction from the cultured mycelia of Fomitopsis pinicola starts with seed culturing the mycelia of Fomitopsis pinicola. After sub-culturing for enrichment, Fomitopsis pinicola is inoculated into a sterile and cold potato medium and cultured. The resulting culture is neutralized and precipitated with ethanol. The precipitate is dialyzed against distilled water to yield a desired extract. The neutralization is preferably conducted to a pH of 6.5 with sodium hydrogen carbonate (NaHCO ), but is not limited thereto.
[30] The term "diseases attributable to the increased activity of aldose reductase", as used herein, is used to mean a condition in which diabetes complications, such as cataracts or renal failure, are caused by the increased intracellular level of sorbitol, reduced from glucose by aldose reductase, which generates osmotic stress due to its low permeability through the cell membrane, thus injuring the eye lens, the retina, and the glomeruli of the kidneys (refer to FIG. 1).
[31] The extract from Fomitopsis pinicola according to the present invention was assayed for preventive or suppressive activity against diseases attributable to the increased activity of aldose reductase and diabetes-induced hyperlipidemia as follows. First, the extract was orally administered to rats in which diabetes mellitus had been induced with STZ (streptozotocin). After being raised, each rat was sacrificed to excise the eye lens and kidneys, which were then homogenized in ice. The homogenate was analyzed for the activity of aldose reductase, having an influence on the incidence of diabetes complications. In addition, blood samples were measured for levels of triglycerides, total cholesterol, HDL cholesterol, and LDL cholesterol to determine whether the extract of the present invention could inhibit diabetes-induced hyperlipidemia.
[32] Furthermore, in order to identify the principle which brought about the inhibitory effect, the Fomitopsis pinicola extract is analyzed for ingredients and the molecular weights thereof. In this regard, the Fomitopsis pinicola extract was fractioned and purified through DEAE-cellulose ion exchange resin and a Sepharose CL-4B gel column, followed by methylation analysis using gas chromatography.
[33] A better understanding of the present invention may be obtained in light of the following examples, which are set forth to illustrate, but are not to be construed to limit the present invention. Mode for the Invention
[34] EXAMPLES
[35] EXAMPLE 1 : Preparation of the Fruit Body and Mycelial Extract of Fomitopsis pinicola
[36]
[37] EXAMPLE 1-1 : Preparation of the Fruit Body of Fomitopsis pinicola with Hot
Water
[38] 90 Grams of the fruit body of Fomitopsis pinicola, purchased from Jeseng Farm, located in Pohang City, Korea, were finely sectioned to a mean size of 5x5 mm, pulverized, added to 2.5 liters of water, and heated at 100°C for 24 hrs. The resulting solution was concentrated at 40°C to a volume of 250 mL, followed by precipitation with ethanol to produce an alcohol-insoluble material. The precipitate, insoluble in alcohol, was freeze-dried to yield a hot- water extract of the fruit body of Fomitopsis pinicola.
[39]
[40] EXAMPLE 1-2: Preparation of the Mycelial Extract of Fomitopsis pinicola with
Alkali
[41]
[42] 90 Grams of the fruit body of Fomitopsis pinicola, purchased from Jeseng Farm, located in Pohang City, Korea, were finely sectioned to a mean size of 5x5 mm, pulverized, swelled for 1 hr in IN KOH (1:1, w/v), and homogenized using a ho- mogenizer. Following filtration through a 100 mesh sieve, the filtrate was neutralized with cone. HCl, washed with distilled water and dried at 60°C to give an alkali extract of the fruit body of Fomitopsis pinicola.
[43]
[44] EXAMPLE 1-3: Preparation of Extract from Cultured Mycelia of Fomitopsis pinicola
[45]
[46] Seed mycelia of Fomitopsis pinicola, obtained from Jeseng Farm, located in Pohang
City, Korea, were inoculated on a YM agar plate (yeast extract: 0.5%(w/v), peptone: 0.5%(w/v), malt extract: 0.2%(w/v), glucose: 1.0%(v/v), agar: 2.0%(w/v), pH 6.5) and sub-cultured at 30°C every 15 days. The mycelia were seed cultured in YM broth using a rotary agitator (150 rpm).
[47] After culturing for 10 days, the mycelia were inoculated in a sterilized (120°C, 30
min), cold potato medium (water: 16 L, potato powder: 300 g, glucose: 150 g, peptone: 0.1 g) to an amount of 2% (v/v), and cultured at 30°C for 10 days in a rotary agitator operating at 150 rpm with sterile air (10cm /min) provided thereto. Then, neutralization with sodium hydrogen carbonate (NaHCO ) to a pH of 6.5 was conducted, followed by precipitation with 10 volumes of ethanol.
[48] The precipitate was dialyzed with distilled water for 48 hrs using a membrane with a molecular weight cutoff of 3,000 to obtain a cultured mycelial extract of Fomitopsis pinicola.
[49] [50] EXAMPLE 2: Preventive Effect of Fomitopsis pinicola Extract on Diabetes Complications
[51] [52] EXAMPLE 2-1: Experimental Animals and Method [53] [54] SD male rats, each having body weight of 200+5 g, were divided into 5 groups of 7, which were respectively set as a normal control group (NC), a diabetes mellitus control group (DM), in which diabetes mellitus was induced through STZ, a diabetes mellitus- induced, hot-water extract-administered group (DM-WE) which was administered with 1% of the hot- water extract after treatment with STZ, a diabetes mellitus-induced, alkali extract-administered group (DM-AE) which was administered with 1% of the alkali extract after treatment with STZ, and a diabetes mellitus-induced, cultured mycelial extract- administered group (DM-CM) which was administered with 1 % of the cultured mycelial extract after treatment with STZ. Each of the groups was reared for four weeks according to the dietary schedules of Table 1, below. In order to induce diabetes mellitus, STZ (streptozotocin 55 mg/kg) was intramuscularly injected. Animals which had a blood sugar level of 300 mg/dL, measured 48 hrs after injection with STZ, were regarded as having diabetes mellitus induced therein. Blood sugar levels were measured using a bio-sensor and a kit.
[55] Table 1 Basic Dietary Composition for Animal Test (g/kg)
[56] AIN-mineral mix(g/kg): Calcium lactate 620.0, sodium chloride 74.0, potassium phosphate dibasic 220.0, potassium sulfate 52.0, magnesium oxide 23.0, manganous carbonate 3.3, ferric citrate 6.0, zinc carbonate 1.0, copper carbonate 0.2, potassium iodide 0.01, sodium selenite 0.01 and potassium chromium sulfate 0.5 were mixed to form a total weight of 1,000 g and finely powdered
[57] AIN- vitamin mix(mg/kg): thiamin hydrochloride 600, riboflavin 600, pyridoxine hydrochloride 700, nicotinic acid 3,000, calcium D-pantothenate 1,600, folic acid 200, D-biotin 20, vitamin B 12 2.5, vitamin A 400,000 IU, vitamin D3 100,000 IU, vitamin E 7,500 IU and vitamin K 75 were mixed to form a total weight of 1,000 g and finely powdered.
[58] [59] In addition, while being fed four weeks according to a different dietary schedule, the experimental animals were observed for weight gain, food intake, and feed efficiency ratio (see: Table 2). The DM group was remarkably decreased in weight gain and feed efficiency ratio compared with the NC group. The DM-AE group, although unable to keep pace with the NC group, was found to significantly increase in weight gain and feed efficiency ratio compared to the DM group. Considerable increases in food intake were observed in the DM, DM-WE, and DM-CM groups compared to the NC group, whereas the food intake of the DM-AE group was recovered to a level comparable to that of the NC group. As for feed efficiency ratio, it was considerably decreased with all experimental groups compared to the NC group,
but all of the groups administered with Fomitopsis pinicola extract were observed to have a feed efficiency ratio superior to that of the DM group.
[60] Table 2
Effect of 4- Week Administration with Fomitopsis pinicola Extracts on Weight Gain, Diet Intake and Feed Efficiency Ratio of Diabetes Mellitus-Induced Rats
[61] NC: normal control, DM: diabetes mellitus control, DM-WE: 1% of Fomitopsis pinicola fruit body hot-water extract was administered after treatment with STZ, DM- AE: 1% of Fomitopsis pinicola fruit body alkali extract was administered after treatment with STZ, DM-CM: 1% of the cultured mycelial extract of Fomitopsis pinicola was administered after treatment with STZ
[62] feed efficiency ratio: weight gain/dietary intake
[63] [64] After being fed with the experimental diets for 4 weeks, the animals were starved for 16 hrs with only water fed thereto. They were etherized and subjected to laparotomy along the ventral median line to expose the ventral aorta, from which blood was then sampled and analyzed for sugar level. The kidneys and the eye lens were also excised and homogenized on ice in a homogenizer to obtain a postmitochondrial fraction, which was analyzed for the activity and level of aldose reductase (AR).
[65] [66] EXAMPLE 2-2: Preventive Effect of Fomitopsis pinicola Extracts on Diabetes Complications
[67] [68] Diabetes complications, such as cataracts, peripheral neuritis, pancreatic injury, etc., are known to be induced upon the metabolism of glucose through the polyol pathway instead of through glycosis. The polyol pathway takes place when hexokinase, which serves as the first step enzyme in anaerobic glycolysis, is saturated. Excess glucose is
reduced to sorbitol via aldose reductase, the first step enzyme in the polyol pathway. An abundance of intracellular sorbitol generates osmotic stress due to its low permeability through the cell membrane, so that an excessive amount of water is introduced into the cell, thus injuring the non-insulin dependent organs, such as eye lenses, peripheral nerves, and the kidneys.
[69] Therefore, data on the activity of aldose reductase in the eye lens and kidney samples prepared in Example 2-1 would give information about the preventive effect of the Fomitopsis pinicola extracts of the present invention on diabetes complications.
[70] The activity of aldose reductase was analyzed according to the method of Hayman and Kinoshita (1965), in which, while lithium sulfate, NADPH and DL-α-glycerol were reacted at 25°C in the presence of the enzyme in 50 mM PBS (pH 6.2), decreasing NADPH levels were measured at 340 nm.
[71]
[72] EXAMPLE 2-2-1 : Suppressive effect on activity of aldose reductase in eye lens
[73]
[74] While the hot- water extract from Fomitopsis pinicola fruit bodies was added into the vial and a postmitochondrial fraction obtained by centrifuging a homogenate of the rat eye lens was used as an enzyme source, the aldose reductase was monitored for activity. The results are given in FIGS. 2 and 3. As seen in the plots of FIGS. 2 and 3, the aldose reductase activity was decreased in a manner dependent on the concentration of the hot- water extract. At a concentration of 125 μl/ml of the extract, the aldose reductase activity was reduced by as much as about 50% compared to that of the control. In addition, the aldose reductase activity change with the addition of the Fomitopsis pinicola fruit body extract was analyzed in terms of kinetics. The enzyme was remarkably increased in Km without variation of Vmax.
[75]
[76] EXAMPLE 2-2-2: Suppressive effect on activity of aldose reductase in kidney
[77]
[78] Postmitochondrial fractions obtained by centrifuging the homogenates of the kidneys were analyzed for aldose reductase (AR) activity. The DM group, in which diabetes mellitus was induced by STZ, was increased approximately 47% in AR activity compared to the NC group. An approximately 25% reduction was observed in the AR activity of the DM-AE group compared to the DM group. It was also found that both the DM-WE group and the DM-CM group tended to decrease in AR activity.
[79] Table 3
Effect of 4- Week Administration with Fomitopsis pinicola Extracts on Renal AR Activity of Diabetes Mellitus-Induced Rats
[80] υNC: normal control, DM: diabetes mellitus control, DM-WE: 1% of Fomitopsis pinicola fruit body hot-water extract was administered after treatment with STZ, DM- AE: 1% of Fomitopsis pinicola fruit body alkali extract was administered after treatment with STZ, DM-CM: 1% of the cultured mycelial extract of Fomitopsis pinicola was administered after treatment with STZ
[81] [82] EXAMPLE 3: Suppressive Effect of Fomitopsis pinicola Extract on Diabetes Mellitus-Induced Hyperlipidemia
[83] [84] The same experimental groups and diets as in Example 2 were conducted. Following the diet programs for 4 weeks, the five experimental groups were measured for blood levels of triglycerides, total cholesterol, LDL cholesterol and HDL cholesterol. For the measurement of blood levels of triglycerides, total cholesterol and HDL cholesterol, commercially available kits were used (AM 157S-K, AM 202-K, AM 203-K, Asanpharm Co., Korea). The level of LDL cholesterol in the blood was calculated according to the method of Fridwell et al. (1972).
[85] A significant increase in blood triglyceride level was observed in the DM group compared to the NC group. However, the blood triglyceride level of the DM-AE group recovered to the same level as that of the NC group. Both the DM-WE group and the DM-CM group were observed to have blood triglyceride levels comparable to that of the DM group (see: Table 4).
[86] Table 4
Effect of 4- Week Administration with Fomitopsis pinicola Extracts on Blood Triglyceride Level of Diabetes Mellitus-Induced Rats
[87] NC: normal control, DM: diabetes mellitus control, DM-WE: 1% of Fomitopsis pinicola fruit body hot-water extract was administered after treatment with STZ, DM- AE: 1% of Fomitopsis pinicola fruit body alkali extract was administered after treatment with STZ, DM-CM: 1% of the cultured mycelial extract of Fomitopsis pinicola was administered after treatment with STZ
[88] [89] The DM-AE group was decreased about 18% in total blood cholesterol level compared to the DM group. Both the DM-AE group and the DM-CM group tended to decrease in total blood cholesterol level, although there was no significance (see: Table 5).
[90] Table 5
Effect of 4- Week Administration with Fomitopsis pinicola Extracts on Total Blood Cholesterol Level of Diabetes Mellitus-Induced Rats
[91] υNC: normal control, DM: diabetes mellitus control, DM-WE: 1% of Fomitopsis pinicola fruit body hot-water extract was administered after treatment with STZ, DM- AE: 1% of Fomitopsis pinicola fruit body alkali extract was administered after treatment with STZ, DM-CM: 1% of the cultured mycelial extract of Fomitopsis pinicola was administered after treatment with STZ
[92] [93] As for blood LDL cholesterol level, it increased remarkably, by about 95%, in the DM group, but decreased significantly in the DM-AE group, unlike the DM group. The DM-AE group was observed to have a blood LDL cholesterol level comparable to that of the NC group. Also, a significant decrease was found in the DM-CM group, compared to the DM group. The DM-WE group tended to decrease in blood LDL cholesterol level, although this was not significant (see: Table 6).
[94] Table 6
Effect of 4- Week Administration with Fomitopsis pinicola Extracts on Blood LDL Cholesterol Level of Diabetes Mellitus-Induced Rats
[95] υNC: normal control, DM: diabetes mellitus control, DM-WE: 1% of Fomitopsis pinicola fruit body hot-water extract was administered after treatment with STZ, DM- AE: 1% of Fomitopsis pinicola fruit body alkali extract was administered after treatment with STZ, DM-CM: 1% of the cultured mycelial extract of Fomitopsis pinicola was administered after treatment with STZ
[96] [97] All of the experimental groups administered with the extracts of the present invention were observed to be increased in blood HDL cholesterol level, but with no significance (see: Table 7).
[98] Table 7
Effect of 4- Week Administration with Fomitopsis pinicola Extracts on Blood HDL Cholesterol Level of Diabetes Mellitus-Induced Rats
[99] υNC: normal control, DM: diabetes mellitus control, DM-WE: 1% of Fomitopsis pinicola fruit body hot-water extract was administered after treatment with STZ, DM- AE: 1% of Fomitopsis pinicola fruit body alkali extract was administered after treatment with STZ, DM-CM: 1% of the cultured mycelial extract of Fomitopsis pinicola was administered after treatment with STZ
[100] Taken together, the data thus obtained in the examples demonstrate that the administration of the Fomitopsis pinicola extracts to diabetes mellitus-induced rats for four weeks reduces blood levels of triglycerides, total cholesterol and LDL cholesterol, with the best effect with the alkali extract from Fomitopsis pinicola fruit bodies.
[101]
[102] EXAMPLE 4: Qualitative Assay for Fomitopsis pinicola Extracts
[103] [104] Fomitopsis pinicola extracts of the present invention were identified as preventors of diabetes mellitus complications as well as suppressors of diabetes mellitus-induced hyperlipidemia, as evident in Examples 2 and 3. In order to examine the principle of the effects, the Fomitopsis pinicola extracts were qualitatively analyzed.
[105] The Fomitopsis pinicola fruit hot- water extract, the Fomitopsis pinicola fruit body alkali extract, and the cultured mycelial extract of Fomitopsis pinicola, prepared as described above, were fractioned and purified through DEAE-Cellulose (Cl ) ion exchange resin and Sepharose CL-4B gel according to a well-known method (see, Lee Shin young, Kang Tae soo, Structure Analysis of Antitumoral Exo-polysaccharide (BWS) obtained from submerged cultivation of Ganoderma lucidum mycelium, The Korean J. Mycology, 27: 76-81, (1999)), followed by methylation analysis using gas chromatography. For the measurement of molecular weight, dextran, having MWs of 2,000,000, 500,000, and 300,000 (Sigma), was used. Absorbance at 280 nm was utilized to detect the protein composition of the fractions. Six-carbon sugars were analyzed according to the anthrone method (see, Spiro RG, Analysis of sugars found in glycoprotein in Method in Enzymology, Academic Press, New York 8: 4-10, (1966)).
[106] Polysaccharides obtained from the Fomitopsis pinicola fruit body hot-water extract, alkali extract and cultured mycelial extract were subjected to affinity chromatography to determine their configurations. No saccharides were detected in the absorption region, indicating that the polysaccharides were of β structure. Methylation analysis gave detailed information, indicating that, as shown in Table 8, 2,3,4,6-tetramethyl glucose and 2,4,6-trimethyl glucose were detected, evincing the presence of β- 1,3-glucan, and that β-l,6-heterogalactomannan was also present.
[107] Taken together, the data demonstrated that one main component of the Fomitopsis pinicola extract was identified as β-l,3-glucano-β-l,6-heterogalactomannan, in which β-l,3-glucan is linked to β-l,6-heterogalactomannan. This complex polysaccharide was found to be a proteoglycan, ranging in molecular weight from 300,000 to 500,000 as measured by gel filtration.
[108] Table 8
Structure Analysis of Polysaccharides from Fomitopsis pinicola Fruit Body Extracts and Cultured Mycelial Extract
[109]
Industrial Applicability
[HO] Fruit body extracts and cultured mycelial extracts of Fomitopsis pinicola according to the present invention effectively inhibit the renal and retinal aldose reductase activity and decrease blood levels of triglycerides, total cholesterol and LDL cholesterol, thereby finding various applications for the development of functional foods for preventing diabetes mellitus complications and suppressing diabetes mellitus-induced hyperlipidemia.
[111] [112] The present invention has been described in an illustrative manner, and it is to be understood that the terminology used is intended to be in the nature of description rather than of limitation. Many modifications and variations of the present invention are possible in light of the above teachings. Therefore, it is to be understood that within the scope of the appended claims, the invention may be practiced otherwise than as specifically described.
Claims
[1] A composition, effective for the prevention or suppression of diseases attributable to the increased activity of aldose reductase or diabetes mellitus- induced hyperlipidemia, comprising a fruit body extract or cultured mycelial extract of Fomitopsis pinicola.
[2] The composition according to claim 1, wherein the fruit body extract is a hot- water extract or an alkali extract.
[3] The composition according to claim 2, wherein the hot-water extract is prepared by cutting Fomitopsis pinicola fruit bodies into fine pieces, pulverizing the pieces, heating the pulverized pieces in water, concentrating the aqueous solution, precipitating the solution with ethanol, and freeze-drying the precipitate, in order.
[4] The composition according to claim 3, wherein the pulverized pieces of the fruit bodies are heated at 100°C for 24 hours and the aqueous solution is concentrated at 40°C to one tenth of the initial volume.
[5] The composition according to claim 2, wherein the alkali extract is prepared by cutting Fomitopsis pinicola fruit bodies into fine pieces, pulverizing the pieces, swelling the pulverized pieces in IN KOH, homogenizing the pieces, filtrating the homogenate, neutralizing the filtrate, washing the neutralized filtrate with distilled water, and drying the washed filtrate at 60°C, in order.
[6] The composition according to claim 5, wherein the pulverized pieces of the fruit bodies are mixed with IN KOH in a ratio of 1:1 (w/v), left to swell for 1 hour, homogenized, filtered through a 100 mesh sieve, and neutralized with cone. HCl.
[7] The composition according to claim 1, wherein the cultured mycelial extract is prepared by seed- and sub-culturing mycelia of Fomitopsis pinicola, inoculating the mycelia in a sterile and cold potato medium, neutralizing the culture, precipitating with ethanol, and dialyzing the precipitate against distilled water.
[8] The composition according to claim 7, wherein the mycelia are inoculated in the potato medium to an amount of 2% (v/v), and the culture is neutralized with sodium hydrogen carbonate (NaHCO ) to a pH of 6.5.
[9] The composition according to claim 1, wherein the diseases attributable to the increased activity of aldose reductase include a diabetes mellitus complication.
[10] The composition according to claim 9, wherein the diabetes mellitus complication is cataract or renal failure.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020060001430 | 2006-01-05 | ||
KR10-2006-0001430 | 2006-01-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007078157A1 true WO2007078157A1 (en) | 2007-07-12 |
Family
ID=38228444
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2007/000055 WO2007078157A1 (en) | 2006-01-05 | 2007-01-04 | Fomitopsis pinicola extract and a process for manufacturing the same |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2007078157A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116606745A (en) * | 2023-05-16 | 2023-08-18 | 中国林业科学研究院森林生态环境与自然保护研究所(国家林业和草原局世界自然遗产保护研究中心) | Wood rot fungus composite microbial inoculant and application thereof in preventing and treating pine wood nematode disease |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4830371A (en) * | 1971-08-20 | 1973-04-21 | ||
KR20050060726A (en) * | 2003-12-17 | 2005-06-22 | 김천환 | Hypoglycemics including fomitosis pinicola extraction and preparing method thereof |
WO2005067955A1 (en) * | 2004-01-06 | 2005-07-28 | Paul Stamets | Antimicrobial activity from medicinal mushrooms |
-
2007
- 2007-01-04 WO PCT/KR2007/000055 patent/WO2007078157A1/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4830371A (en) * | 1971-08-20 | 1973-04-21 | ||
KR20050060726A (en) * | 2003-12-17 | 2005-06-22 | 김천환 | Hypoglycemics including fomitosis pinicola extraction and preparing method thereof |
WO2005067955A1 (en) * | 2004-01-06 | 2005-07-28 | Paul Stamets | Antimicrobial activity from medicinal mushrooms |
Non-Patent Citations (2)
Title |
---|
DATABASE MEDLINE [online] USUI T. ET AL.: "Investivation of the heterogeneity of hetrogalactan from the fruit bodies of Fomitopsis pinicola, by employing concanavalin A-Sepharose affinity chromatography", XP003015393, Database accession no. (NLM6894749) * |
J. OF BIOCHEMISTRY, JAPAN, vol. 89, no. 4, April 1981 (1981-04-01), pages 1029 - 1037 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116606745A (en) * | 2023-05-16 | 2023-08-18 | 中国林业科学研究院森林生态环境与自然保护研究所(国家林业和草原局世界自然遗产保护研究中心) | Wood rot fungus composite microbial inoculant and application thereof in preventing and treating pine wood nematode disease |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Lo et al. | Medicinal mushrooms for glycemic control in diabetes mellitus: history, current status, future perspectives, and unsolved problems | |
Wu et al. | Antidiabetic and antioxidant activities of eight medicinal mushroom species from China | |
US6468542B2 (en) | Germination activated Ganoderma lucidum spores and method for producing the same | |
KR100787633B1 (en) | Tea and Tea Manufacturing Method for Improving Liver Function and Curing of Hangover | |
Oluba et al. | Evaluation of the hypoglycemic effect of aqueous extract of Ganoderma lucidum on STZ-induced diabetic wistar rats | |
Sonawane et al. | Hypoglycemic and anticataract activity of crude exopolysaccharides of medicinal mushroom Phellinus badius on streptozotocin-induced diabetic rats and goat eye lenses respectively | |
Zhuang et al. | Medicinal Value of Culinary-Medicinal Maitake Mushroom Grifola frondosa (Dicks.: Fr.) SF Gray (Aphyllophoromycetideae). Review. | |
CN104643032A (en) | Extraction method of active ingredients of medicinal fungi | |
JP5993112B2 (en) | Antidepressant | |
KR20110115252A (en) | Functional fermented-medicinal herbs that are effective to improve liver function, improve serum lipid levels, control blood pressure, improve atopic dermatitis, skin whitening, and functional fermented-medicinal herbs manufactured thereby | |
JP3284097B2 (en) | Biological antioxidant function enhancer | |
JP4602674B2 (en) | Maltase inhibitor | |
Kaur et al. | Evaluation of carbohydrate metabolism inhibition by some species of medicinal mushrooms from India | |
Choi et al. | Antihyperglycemic and antioxidant activities of polysaccharide produced from Pleurotus ferulae in streptozotocin-induced diabetic rats | |
WO2007078157A1 (en) | Fomitopsis pinicola extract and a process for manufacturing the same | |
KR20090043758A (en) | Composition for improvement of fatty liver | |
Watanabe et al. | Pharmacological investigation of Ceraceomyces tessulatus (Agaricomycetes) in mice with nonalcoholic steatohepatitis | |
Choi et al. | Effect of Dongchunghacho (Cordyceps militaris) on hyperglycemia and dyslipidemia in type 2 diabetic db/db mice | |
KR101228554B1 (en) | The Fermentation Forming Method of Citrus Sunki And The Product thereof | |
An et al. | Hangover relieving effect of Sanghwang mushroom mycelium cultured in germinated buckwheat | |
KR100859986B1 (en) | Fomitopsis pinicola Extract Having Diabetes Complication Preventive Effect and The Use Thereof | |
WO2007091827A1 (en) | Extract from submerged culture of fomitopsis pinicola mycelia and hypoglycemic composition comprising the same | |
KR20200016610A (en) | Composition for Improvement of Fatty Liver | |
KR100859983B1 (en) | Fomitopsis pinicola Extract Having Inhibitory Effect of Reactive Oxygen Spices Generated by Diabetes Mellitus and The Use Thereof | |
CN117981877B (en) | Anti-alcohol liver-protecting composition and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 07700847 Country of ref document: EP Kind code of ref document: A1 |